Roche has submitted a supplemental biologics license application in the US seeking to expand the use of Kadcyla to include the adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.